Laduviglusib - HY-10182
Nur noch %1 verfügbar
Catalog #
HY-10182
Ab
74,00 €
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy[1][2][3].
| Datasheet URL | http://file.medchemexpress.com/batch_PDF/HY-10182/Laduviglusib-DataSheet-MedChemExpress.pdf |
|---|---|
| Shipping | Room Temperature |
| Application | Cancer-Kinase/protease |
| Alternative Names | CHIR-99021; CT99021 |
| CAS | 252917-06-9 |
| Storage | -20°C, 3 years; 4°C, 2 years (Powder) |
| MWT | 465.34 |
| Solubility | DMSO : 16.67 mg/mL (ultrasonic) |
| Clinical Information | No Development Reported |
| Target | Autophagy;GSK-3;Organoid;Wnt;β-catenin |
| Application: | Cancer-Kinase/protease |
|---|